🔗 Share this article

While the United States proceeds with unprecedented adjustments to its vaccine guidelines, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on Covid shots during the global health crisis and has focused upon possible deaths following Covid vaccination in her short tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to reveal radical revisions to the childhood vaccine schedule recently, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of alignment with much of the international standard with little proof for public health gain. This reveal has been postponed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to run the center this calendar year.

A Shift at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Dr. Prasad consolidate power at the FDA – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending some childhood vaccine recommendations in the US so as to align more in line with Denmark's approach, a nation with nationalized medicine and a population roughly the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Qualifications

Høeg has no obvious background in pharmaceutical research, regulation or leadership, which has been customary for previous directors of the CBER. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in running a major agency. She lacks background in industry regulation.”

Former heads of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who led CBER have had.”

This division has an vast portfolio at the agency, Woodcock stated.

“The public just zeroes in on the novel medication approvals, but the generic program authorizes numerous generic drugs. There is also a biosimilars division, OTC medication office and so forth, and all of those must be supervised,” Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a major administrative element to the position, which supervises more than 5,000 staff members. “It’s a massive management job, if you execute it properly,” Woodcock said.

Response and Disputed Initiatives

Regarding concerns about Høeg’s credentials and whether this selection indicates increased cooperation among agency officials on immunizations, a representative stated that the “questions rely on inaccurate assumptions”.

“Her experience matches the duties of her position,” the spokesperson explained, citing the period Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s new fast-track approval initiative, a disputed one-day therapy clearance system that reportedly troubled her preceding directors. “By what process are these therapies being chosen for this expedited pathway? Who takes the choices?” Dr. Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the FDA looks to be trending towards laxer regulations of pharmaceuticals, with the exception of vaccines.”

Established Past Work on Vaccines

With immunizations, Dr. Høeg has a more established, if concerning, history, critics said. She authored a research paper using non-validated public submissions to determine the frequency of myocarditis following COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccinations are riskier than they are.

Part of her “policy goals” for the new government included altering rules for recently developed shots and halting “unnecessary” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has allegedly suggested preventing teenage boys from getting Covid vaccinations.

“She’s an complete true believer who starts off with her conclusions and tailors the evidence to accommodate the evidence in a extremely misleading, dishonest way,” Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|